Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.650-0.700 for the period, compared to the consensus earnings per share estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Amneal Pharmaceuticals Trading Down 0.6 %

Shares of AMRX opened at $8.38 on Friday. The stock’s 50-day moving average price is $8.08 and its two-hundred day moving average price is $8.31. Amneal Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $9.48. The company has a market capitalization of $2.60 billion, a PE ratio of -12.32 and a beta of 1.10.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $12.00 in a research note on Monday. Finally, StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $10.60.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 160,000 shares of company stock valued at $1,292,000 in the last 90 days. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.